help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2004-1674
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/5/2556    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pringle, P. J.
Right arrow Articles by Hindmarsh, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pringle, P. J.
Right arrow Articles by Hindmarsh, P. C.
Related Collections
Right arrow Pediatric Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 5 2556-2562
Copyright © 2005 by The Endocrine Society

The Influence of Cigarette Smoking on Antenatal Growth, Birth Size, and the Insulin-Like Growth Factor Axis

P. Jane Pringle, Michael P. P. Geary, Charles H. Rodeck, John C. P. Kingdom, Simon Kayamba-Kay’s and Peter C. Hindmarsh

Centre for Human Growth and Maturation at the London Centre for Paediatric Endocrinology and Metabolism (P.J.P., S.K.-K., P.C.H.) and Department of Obstetrics and Gynaecology (C.H.R.), University College London, London W1T 3AA, United Kingdom; Department of Obstetrics and Gynaecology (M.P.P.G.), Rotunda Hospital, Dublin 1, Ireland; and Program in Development and Fetal Health (J.C.P.K.), Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto M5G 1X5, Canada

Address all correspondence and requests for reprints to: Dr. P. C. Hindmarsh, Centre for Human Growth and Maturation, Cobbold Laboratories, Middlesex Hospital, Mortimer Street, London W1T 3AA, United Kingdom. E-mail: p.hindmarsh{at}ucl.ac.uk.


    Abstract
 Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 References
 
Background: Maternal smoking during pregnancy is associated with a reduction in birth size. Very few studies have collated changes in fetal biometry, neonatal anthropometry, biochemical factors involved in fetal growth, and measures of uterine and umbilical blood flow.

Methods: We related smoking status in 1650 low-risk, singleton Caucasian pregnancies delivering at term to measures of fetal growth, uterine and umbilical artery blood flow, placental appearance, birth size, and cord concentrations of IGF-I and -II and IGF binding protein (IGFBP)-3.

Results: Mothers who smoked in pregnancy were younger (P < 0.001) and shorter (P = 0.03) and from lower socioeconomic groups (P < 0.001). Mean umbilical artery blood flow at 20 wk gestation was not associated with smoking status but was significantly higher in smokers at 30 wk (P = 0.006). Uterine artery blood flow was unaffected. Smoking was associated with an increase in the percentage of abnormal placentas in a dose-dependent manner and with a 3.1-fold increased risk (odds ratio 3.1, 95% confidence interval 1.3–7.6) of abnormal umbilical artery blood flow (P = 0.009). Smoking was associated with a reduction in fetal femur length (P = 0.005) and abdominal circumference as well as birth weight, length, and head circumference but not skinfold thickness. Cord plasma concentrations of IGF-I and IGFBP-3 were lower in the babies of mothers who had smoked (P = 0.02 and P = 0.01, respectively).

Conclusion: We concluded that maternal smoking is associated with an altered placental appearance on ultrasonography, increased umbilical artery blood flow resistance, and a reduction in longitudinal and intraabdominal organ growth. Circulating concentrations of IGF-I and IGFBP-3 along with measures of birth size but not markers of body fat are reduced, suggesting smoking results in a reduction in organ size and function.


    Introduction
 Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 References
 
MATERNAL SMOKING CONSTRAINS fetal growth with reductions reported in birth weight of between 90 and 200 g (1, 2, 3, 4, 5). The effect of smoking tends to override factors that increase birth weight (6). The components of body composition influenced by smoking appear to be length, head circumference, and peripheral muscle mass with little effect on fat (5, 7).

Despite the detrimental effect of maternal smoking during pregnancy, little is known of the underlying mechanism(s) constraining growth. Reductions in uterine or umbilical artery blood flow have followed acute or chronic cigarette smoke inhalation (8, 9, 10). Clinical experience suggests that the placentas of mothers who smoke are small and gritty, whereas epidemiological studies indicate that placental weight may be increased (4), decreased (8), or unchanged (5, 11, 12). These discrepancies probably relate to the proportion of heavy smokers in the cohort, a factor known to influence placental angiogenesis (11, 13). Chronic or acute hypoxia and the presence of carbon monoxide in the maternal circulation could result in altered oxygen delivery to the fetus (14). All these factors may contribute to smaller babies born to mothers who smoke during pregnancy.

Size and shape at birth is a composite of several factors. IGF-I and -II are important for fetal growth as evidenced by animal (15) and clinical studies (16, 17, 18, 19, 20). It is likely that the effects of smoking on growth are mediated in part by the IGF system, which represents a final common pathway for growth in fetal life. To address this, we studied the plasma concentrations of the IGF family in cord blood from the pregnancies of smokers and nonsmokers and controlled for confounding factors such as chronic uteroplacental hypoxia-ischemia.


    Patients and Methods
 Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 References
 
Study cohort

Patients were consecutive mothers booked at University College London Hospitals between April 1996 and July 1997 (5). A total of 1790 mothers fulfilled the entry criteria and 1650 (92%) agreed to participate. They did not differ in terms of clinical or pregnancy outcomes from those who refused. Inclusion criteria were first prenatal visit before 20 wk, ultrasound examination demonstrating a structurally normal single fetus, and a Caucasian mother. Exclusion criteria were increased nuchal translucency or evidence of a major malformation in the ultrasound scan (n = 6) or maternal steroid use for chronic inflammatory or thrombotic disorders (n = 16). Menstrual dates were used to assign gestational age unless the first ultrasound measurement differed by more than 7 d. Current cigarette consumption was categorized as never smoked (group 1) (n = 870), stopped on becoming pregnant (group 2) (n = 117), less than 10 (group 3) (n = 115), 10–20 (group 4) (n = 90), or more than 20 (group 5) (n = 26) cigarettes per day. Pregnancy complications (21) were noted along with mode of delivery.

At 20 and 30 wk gestation, further ultrasound studies were conducted to measure fetal growth using the parameters of head and abdominal circumferences and femur length using an Acuson 128/Xpi (Mountain View, CA) ultrasound machine with a 5-MHz curvilinear transducer. Participation by mothers was high for both the second- (96%) and third-trimester scans (84%), and reasons for not performing the scans were mainly fetal loss or termination of pregnancy. Only 50 mothers refused both scans and their data were excluded from analysis. Each measurement was the mean of three recordings. The coefficient of variation (CV) of the ultrasound measures was 1% on the 20-wk scan. At the 30-wk scan Doppler ultrasonography of uterine and umbilical artery blood flow was conducted and expressed as the pulsatility index (22). The ultrasonographers were unaware of the smoking status of the women. All blood flow measurements represent the mean of three measurements. Placenta were graded according to Grannum (23) as: grade 0, normal; grade 1, random echogenic areas present; grade 2, basal echogenic areas and indentations in the chorionic plate; and grade 3, echo-poor areas, irregular echogenic areas, and deep indentations in the chorionic plate.

Complete perinatal outcome and neonatal anthropometric data were available in 1484 babies including Apgar scores at 1 and 5 min. Birth weight was measured using electronic self-calibrating scales (Seca, Birmingham, UK), length by Infantometer (Child Growth Foundation, London, UK), and head and midarm circumferences with a metal tape (Holtain, Crymych, UK). Triceps, subscapular and quadriceps skinfolds were measured using skinfold calipers (Holtain, Crymych, UK). Three separate measurements were taken and the mean recorded. The CV of the measurement error for length was 0.15% based on 10 infants, each measured five times by three observers.

After birth and before completion of the third stage of labor, blood was collected into EDTA from the umbilical cord vein. A sample was used to measure cord blood pH and the remainder centrifuged, separated, and plasma stored immediately at –20 C. Assays for IGF-I, IGF-II, and IGF binding protein (IGFBP)-3 were performed in batches within 3 months of collection.

The study was approved by the Research Ethics Committee of University College London Hospitals, and written informed consent for participation was obtained from the mother for herself at the commencement of the study and for her newborn child after delivery.

Hormone assays

IGF-I. IGF-I was measured by a commercial immunoradiometric assay (Nichols Institute Diagnostics, San Juan Capistrano, CA). This is a nonextraction method in which the IGFBPs are separated from the IGF-I by acidification of the sample and excess IGF-II is added to block the binding proteins from recombining with the IGF-I. The within-assay CVs were 4.6 and 3.3% at 61.0 and 292.5 ng/ml, respectively. The between-assay CVs were 15.5 and 11.3% at 88.6 and 240.4 ng/ml. The standards were prepared from recombinant IGF-I and were calibrated against World Health Organization First International Reference Preparation (87/518). The minimum detection limit of the assay was 6 ng/ml. Recovery of recombinant IGF-I (50–100 ng/ml) added to cord serum before acidification was estimated to be 96–98%.

IGF-II

IGF-II was measured by a commercial coated-tube immunoradiometric assay (Diagnostic Science Laboratories, Webster, TX). This is a nonextraction method in which the IGFBPs are separated from IGF-II by dilution and acidification of the sample. The within-assay CVs were 6.5, 3.4, and 4.7% at 245, 409, and 1432 ng/ml, respectively. The between-assay CVs were 14.5 and 7.2% at 273 and 785 ng/ml, respectively. The standards were calibrated against a preparation of recombinant IGF-II. The minimum detection limit of the assay was 12 ng/ml. Studies of IGF-II recovery yielded values ranging between 95 and 98%.

IGFBP-3

IGFBP-3 was measured by a commercial coated-tube immunoradiometric assay (Diagnostic Science Laboratories). Samples were analyzed at 1:100 dilution. The within-assay CVs were 3.9, 3.2, and 1.8% at 7.35, 27.53, and 82.72 µg/liter, respectively. The between-assay CVs were 7.6 and 4.2% at 5.43 and 27.15 µg/liter, respectively. The standards were calibrated against recombinant nonglycosylated IGFBP-3. The minimum detection limit of the assay was 0.5 µg/liter. Estimates of IGFBP-3 using this methodology will include the major proteolytic fragments of IGFBP-3.

Statistics

All data were explored for normality of distribution and log transformed where appropriate. Values for birth weight, length, and head circumference were expressed as SD scores (SDS) using the 1990 British growth reference (24). Relationships between hormonal parameters and anthropometric measures and pregnancy parameters were estimated using Pearson’s correlation coefficient. In investigating the effects of smoking on the birth weight SDS-placental weight relationship analysis of covariance was used to compare differences in slope intercepts after testing for differences in regression slopes (25). Multiple linear regression analysis was used to explore effects of cigarette smoking, cord pH, and Apgar score on cord plasma IGF-I, IGF-II, and IGFBP-3 concentrations. One-way ANOVA with the Student-Newman-Keuls post hoc test was used to determine differences between mean values of the groups. Student’s t test was used to determine differences in cord plasma IGF-I, IGF-II, and IGFBP-3 concentrations between subjects with low (<7) and high (>7) Apgar scores. {chi}2 Analysis was used to determine the distribution of factors such as parity, socioeconomic group, placental Grannum grade, abnormality in umbilical artery blood flow, and Apgar score with respect to smoking habit. Risk estimates were expressed as odds ratios with 95% confidence intervals.


    Results
 Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 References
 
General

Of the 1650 mothers, 1484 delivered a live infant. The 166 who did not deliver consisted of 127 who did not complete the study because they had moved away or were lost to follow-up, 28 who had a miscarriage or termination of pregnancy, and 11 who withdrew from the study. These mothers did not differ in terms of first-attendance characteristics from those who completed the study. Analysis was confined to infants delivered at term (gestation > 37 wk) (n = 1215) in pregnancies uncomplicated by gestational diabetes and chronic uteroplacental hypoxia-ischemia-antepartum hemorrhage, pregnancy-induced hypertension, and preeclampsia.

Mothers who smoked heavily in pregnancy were younger (one-way ANOVA F = 27.4; P < 0.001) and shorter (F = 2.64; P = 0.03) and from socioeconomic groups (SEGP) 4 and 5 (SEGP 1, 96% nonsmokers vs. 56% in SEGP 5 {chi}2 157.5; P < 0.001). Body mass index was not significantly different between smokers and nonsmokers. The maternal age and SEGP effect were interrelated because mothers from SEGPs 4 and 5 were significantly younger than SEGPs 1, 2, and 3 (one-way ANOVA F = 70.1; P < 0.001: Student-Newman-Keuls SEGPs 1, 2, and 3 vs. SEGPs 4 and 5 P < 0.05). Parity did not influence smoking habit. There were no significant differences between the groups in maternal prepregnancy weight, gestation at first antenatal attendance, weight gain during pregnancy (data not shown), gestational age at delivery, blood pressure at first antenatal attendance, or maternal hemoglobin concentration (Table 1Go).


View this table:
[in this window]
[in a new window]
 
TABLE 1. Clinical and anthropometric details of the UCL cohort of mothers at first antenatal visit

 
Uterine and umbilical blood flow studies

Uterine. There was no association between smoking status and mean uterine artery Doppler pulsatility index at the 20 or 30 wk assessment.

Umbilical. Mean umbilical artery Doppler pulsatility index was not different among the groups at 20 wk but at 30 wk was significantly higher in the smokers [group 3, 1.02 (SD 0.16); group 4, 1.02 (SD 0.18); group 5, 1.02 (SD 0.15), compared with the nonsmokers (0.97, SD 0.17) or those who had stopped smoking (1.00, SD 0.16) (one-way ANOVA, F = 3.65; P = 0.006; Student-Newman-Keuls post hoc test, P < 0.05 for smokers vs. the rest)].

Placental ultrasound

Figure 1Go shows a dose-dependent effect of smoking on placental Grannum grade. None had Grannum 3 placentas ({chi}2 310; P < 0.001). The presence of a placenta with Grannum grade 1 or 2 was associated with 3.1-fold increased risk (odds ratio 3.1 95% confidence interval 1.3–7.6) of an abnormal high umbilical artery pulsatility index ({chi}2 6.90; P = 0.009).



View larger version (13K):
[in this window]
[in a new window]
 
FIG. 1. Proportion of individuals with placental Grannum grades 0–2 in relation to smoking status.

 
Placental weight at delivery

In the nonsmoking group, placental weight was related to birth weight SDS (r = 0.56; P < 0.001) and described by the equation: birth weight SDS = 0.004 (placental weight in grams) – 2.58 (Fig. 2Go).



View larger version (9K):
[in this window]
[in a new window]
 
FIG. 2. The relationships of placental weight (kilograms, gray bars) and birth weight expressed as an SDS (black bars) with cigarette use during pregnancy.

 
Smoking was not associated with any change in mean placental weight. The relationship in the smokers between birth weight SDS and placental weight was described by the equation: birth weight SDS = 0.005(placental weight in grams) – 3.46

The intercepts for these two regression equations was significantly different (0.87 SDS or approximately 400 g) (P = 0.001), whereas there was no significant difference between the regression equation slopes.

Fetal growth and birth size

There was no difference in fetal biometric measurements (head and abdominal circumferences and femur length) at 20 wk gestation between those who smoked and those who did not. At 30 wk of gestation there was a significant reduction in femur length (one-way ANOVA, F = 3.73; P = 0.005; nonsmokers significantly greater than other groups, Student-Newman-Keuls, P < 0.05) and to a lesser extent abdominal circumference (one-way ANOVA, F = 3.08; P = 0.015; nonsmokers significantly greater than other groups, Student-Newman-Keuls, P < 0.05). Head circumference was not significantly different as was biparietal diameter (Table 2Go).


View this table:
[in this window]
[in a new window]
 
TABLE 2. Fetal biometry measurements by ultrasound at 30 wk gestation

 
At birth, weight, length, and head circumference were all significantly lower in the smokers, compared with those who did not or had given up smoking (Student-Newman-Keuls, P < 0.05 for groups 1 and 2 vs. groups 3–5). No dose-dependent effect could be discerned (Table 3Go). There was no difference in the frequency of babies with a birth weight SDS lower than the third centile between those who smoked (4.8%) and those who did not (2.4%) ({chi}2 6.37; P = 0.17). However, there was an increase in the frequency of babies with a birth weight SDS less than the 10th centile between those who smoked (19%) and those who did not (7%) ({chi}2 33.2; P < 0.001). No significant effects could be observed on skinfold thickness and midarm circumference. Males were affected to the same extent as females.


View this table:
[in this window]
[in a new window]
 
TABLE 3. Neonatal anthropometric measures

 
IGF axis

Cord plasma IGF-I and IGFBP-3 concentrations were significantly lower in babies that had been exposed to cigarette smoking than in those whose mothers did not or had ceased smoking. Cord plasma concentration of IGF-II was unaffected by smoking status (Fig. 3Go).



View larger version (15K):
[in this window]
[in a new window]
 
FIG. 3. The relationship of smoking to the cord plasma concentrations of IGF-I (upper panel), IGF-II (upper middle panel), IGFBP-3 (lower middle panel), and cord pH (lower panel).

 
The cord plasma IGF-I concentration, but not the cord plasma concentrations of IGF-II and IGFBP-3, was lower in subjects with a low Apgar score (<7) at 1 min [mean IGF-I 63.7 (SD 24.9) ng/ml], compared with those with an Apgar score greater than 7 (mean IGF-1 70.0 ng/ml, SD 25.5) (Student’s t test 2.88; P = 0.004). Low Apgar score at 1 min was not related to smoking ({chi}2 0.81; P = 0.37). At 5 min the Apgar score was not related to any of the cord hormone concentrations.

Cord pH was related to cord plasma IGF-I concentration (r = 0.13; P < 0.001) but not cord plasma concentrations of IGF-II and IGFBP-3. Subjects with low Apgar scores at 1 min had lower cord pH (r = 0.29; P = 0.001). In multiple regression analysis, cord pH and number of cigarettes smoked were important determinants of cord plasma IGF-I concentration but explained only 3% of the variance.

When analysis was confined to patients in whom causes of chronic uteroplacental hypoxia-ischemia were excluded along with pregnancies with Grannum stage 2 placental appearance, abnormal umbilical artery Doppler studies at 30 wk of gestation, and Apgar score less than 7 at 1 min, the relationship of cord plasma IGF-I (one-way ANOVA, F = 3.56; P = 0.007) and IGFBP-3 (one-way ANOVA, F = 4.07; P = 0.003) (n = 852) concentrations with smoking was maintained.

Cord plasma IGF-I concentration was strongly related to all measures of birth size. In multiple linear regression analysis, IGF-I, cigarette smoking, placental weight, maternal height and weight at first presentation, and parity were the main significant determinants of birth size, explaining 52.3% of the variance of birth weight, 20.2% of birth length, and 20.8% of head circumference (Table 4Go).


View this table:
[in this window]
[in a new window]
 
TABLE 4. Interaction of smoking with factors influencing birth size by multiple regression analysis

 

    Discussion
 Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 References
 
These data present a longitudinal assessment of the effects of smoking on placental structure, umbilical artery blood flow, and fetal growth in utero. The results confirm that smoking is associated with a reduction in birth weight, length, and head circumference (1, 2, 3, 4, 5). The effects on growth are detectable at 30 wk of gestation and are associated with an increase in placental echogenicity and increased resistance to blood flow in the umbilical artery. The growth effects at this gestational age are manifest as reductions in femur length and abdominal circumference. The later suggests compromised intraabdominal organ growth, e.g. liver, which might be expected to be associated with a reduction in IGF-I production and reduced birth size (16, 17, 18, 19, 20).

Maternal smoking was most common among socioeconomic groups 4 and 5 who tended to be the youngest mothers, an observation noted in part by others (4). Mothers who smoked were shorter, but there was no difference in maternal weight at presentation between the smoking groups that might suggest explanations for differences in birth size. This would imply, that in this cohort, impaired maternal nutrition at this stage of pregnancy was not a major issue. We have also inferred that both smokers and nonsmokers had similar calorie intakes during pregnancy because maternal weight gains were similar. Furthermore, late gestational studies of food intake suggest that the fetal growth restriction observed in smokers is not related to decreased maternal food intake (26). This does not imply, however, that impaired nutrition in early/midgestation is not an important factor in determining fetal growth in other populations. Maternal hemoglobin concentrations at this early stage of pregnancy were similar among the groups, suggesting that there was little effect on oxygen-carrying capacity, although a change through pregnancy cannot be excluded. An increase in maternal hemoglobin concentration in smokers has been noted in some pregnancies, which might imply a longer-term compromise of oxygen delivery (27).

There was no significant difference in uterine Doppler artery pulsatility index between smokers and nonsmokers, suggesting that altered uterine artery blood flow is an unlikely explanation for the poor intrauterine growth observed. These findings confirm acute and chronic studies of cigarette exposure in pregnant women (8, 9, 10).

Smoking was associated with an increase in the proportion of placentas with abnormal echogenicity, and this effect was dose dependent. Other causes for abnormal placental morphology such as preeclampsia had been excluded. Placental weight was not different in smokers, compared with nonsmokers, despite the fact that birth weight was lower. The relationship between birth weight and placental weight was maintained across the range of cigarettes smoked with an overall reduction of 400 g in those smoking 20 cigarettes per day. This preservation of placental weight probably reflects an increase in placental angiogenesis (13), compensating or attempting to compensate for the compromised areas observed on ultrasound. The degree of angiogenesis and cigarette consumption are presumably the explanations for the variation in placental epidemiology findings in smokers in whom placental weights may be increased (4) or unchanged (5, 11, 12). A reduction in placental weight is probably observed in very heavy smokers (8) in whom marked structural damage to the villous stroma and basement membrane of the fetal capillaries takes place (28). The presence of an ultrasonographically abnormal placenta was associated with an increased chance of detecting an increase in umbilical artery resistance. Although indirect, this suggests that either changes in placental morphology lead to a reduction in umbilical artery blood flow or the effect of smoking is manifest in both structures.

The net effect of smoking on the fetus, whether mediated through altered umbilical artery blood flow, placental function, or a direct toxic effect, was a symmetrical reduction in birth weight, length, and head circumference. Of note, in this cohort, smoking did not increase the incidence of babies that had a birth weight SDS less than the third centile but did increase the numbers with a birth weight SDS less than the 10th centile, suggesting an overall shift of the birth weight distribution in the smoking group. These observations are of particular interest, given the association of small size with increased risk of cardiovascular disease in adult life (29) and suggest that in such analyses maternal smoking status needs to be included. This is important because unless the effect of smoking on organ size is accounted for in the determination of later risk, that risk may be incorrectly ascribed to the effect of birth size per se. The reduction in birth weight did not appear to result from alterations in body fat, as evidenced by the skinfold thickness measures, confirming previous studies (30, 31). Caution needs to be exercised in this interpretation because more precise methods for estimation of body fat were not performed (32). That aside, the data might suggest that the effects of smoking on birth weight reflect changes in organ size, e.g. reduced head circumference and, by inference, brain size as well as other components of body size, e.g. bone as reflected in body length.

There was no difference in fetal anthropometric measures at 20 wk of gestation, which may reflect the sample size required at this stage of gestation to detect an effect. By 30 wk clear differences in femur length and abdominal circumference could be detected but little effect on head circumference. The greater effect on femur length, compared with abdominal circumference, might be expected, given the different growth patterns of length and liver (which must constitute the major component of abdominal circumference). Peak length velocity is attained between 26 and 28 wk of gestation, whereas peak liver growth is later in the third trimester (33). The situation with head circumference is not so easy to explain because our data would suggest that compromised growth takes place during the third trimester, whereas the greatest increase in head circumference takes place in the first trimester. A possible explanation could derive from the fact that nicotinic receptors are present in some brain regions by midgestation (34), and animal studies suggest that this is a critical time period when nicotine exposure reduces brain volume (35).

The IGFs are important determinants of fetal growth (16, 17, 18, 19, 20). In this study the cord plasma IGF-I and IGFBP-3 concentrations were lower in the babies of mothers who had smoked, whereas the cord plasma IGF-2 concentrations were unaffected. This may reflect the fact that IGF-I and insulin are more important for late fetal growth than IGF-II or that there is a compensatory increase in the latter (16). IGF-I appears to be influenced by acute hypoxia-ischemia because it was related to Apgar score at 1 min and cord pH in a manner noted in animal studies (36). However, when analysis was confined to those pregnancies in which acute and chronic uteroplacental hypoxia-ischemia was excluded, the association of smoking with lower cord plasma IGF-I concentration remained. The cord plasma IGF-I concentration appeared to be an independent predictor of birth size, suggesting that an additional explanation for the reduced birth size of infants of mothers who smoke in pregnancy may be a direct action of smoking on IGF generation in the fetal liver.

In conclusion, we have demonstrated in a longitudinal study that smoking in pregnancy is associated with an increase in placental echogenicity, reduced umbilical artery blood, fetal production of IGF-I, and birth size without alterations in uterine artery blood flow and maternal nutritional status. The sequence of associations suggest that smoking induces microvascular changes in the placenta that are associated with an increase in vascular resistance in the umbilical artery. Fetal growth of structures such as the skeleton and liver are compromised during periods of rapid growth, and the alteration in liver size or a direct effect of cigarette smoking on liver IGF-I generation is associated with a reduction in organ growth and in particular a reduction in birth weight. How smoking influences head growth is unclear. Although we describe a sequence of associations, it is possible that the effects of cigarette smoking represent a direct toxic effect with a variable dosing effect on different structures. It would be unwise, however, to overstate the case for the latter because a lack of dose response in some measures (umbilical artery blood flow), compared with others (birth length), may be more of a reflection of the precision of these measures. It also needs to be considered that because circulating IGF-I concentrations are related to IGFBP-3 concentration, the effects of smoking could be due to primary effects on IGFBP-3. Furthermore, because the liver is the primary organ source for circulating IGF-I and IGFBP-3, it might be that a smaller liver leads to lower IGF-I/IGFBP-3 production. Finally, because in many epidemiological studies in which randomization is not possible, the possibility that smoking is a confounder and that the causal agent is not realized remains. What is clear is that smoking cessation before or at the commencement of pregnancy can lead to a normal growth outcome for the baby.


    Footnotes
 
This work was supported by grants from the British Heart Foundation (PG/98133), Children Nationwide UK, and Pharmacia-Upjohn (to P.C.H.). J.C.P.K. is funded by the Program in Development and Fetal Health, Samuel Lunenfeld Institute, and the Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of Toronto.

The study was designed by P. C. Hindmarsh, J. C. P. Kingdom, and C. H. Rodeck. Laboratory analysis was undertaken by P. J. Pringle and M. P. P. Geary, and all authors contributed to analysis of the data and writing of the manuscript. All authors had access to all data in the study, and the responsibility for the decision to submit for publication was a joint one.

There are no conflicts of interest.

First Published Online February 15, 2005

Abbreviations: CV, Coefficient of variation; IGFBP, IGF binding protein; SDS, SD score; SEGP, socioeconomic group.

Received August 20, 2004.

Accepted February 3, 2005.


    References
 Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 References
 

  1. Butler NR, Goldstein H, Ross EM 1972 Cigarette smoking in pregnancy: its influence on birth weight and perinatal mortality. BMJ ii:127–130
  2. Anderson GD, Blidner IN, McClemont S, Sinclair JC 1984 Determinants of size at birth in a Canadian population. Am J Obstet Gynecol 150:236[Medline]
  3. Cliver SP, Goldenberg MD, Cutter GR, Hoffman HJ, Davis RO, Nelson KG 1995 The effect of cigarette smoking on neonatal anthropometric measurements. Obstet Gynecol 85:625–630[Abstract]
  4. Williams LA, Evans SF, Newnham JP 1997 Prospective cohort study of factors influencing the relative weights of the placenta and newborn infant. BMJ 314:1864–1868[Abstract/Free Full Text]
  5. Hindmarsh PC, Geary MP, Rodeck CH, Kingdom JCP, Cole TJ 2002 Intrauterine growth and its relationship to size and shape at birth. Pediatr Res 52:263–268[CrossRef][Medline]
  6. Haworth JC, Ellestad-Sayed JJ, King J, Dilling LA 1980 Relation of maternal cigarette smoking, obesity, and energy consumption to infant size. Am J Obstet Gynecol 138:1185–1189[Medline]
  7. Bernstein IM, Plociennik K, Stahle S, Badger GJ, Secker-Walker R 2000 Impact of maternal cigarette smoking on fetal growth and body composition. Am J Obstet Gynecol 183:883–886[CrossRef][Medline]
  8. Newnham JP, Patterson L, James I, Reid SE 1990 Effects of maternal cigarette smoking on ultrasonic measurements of fetal growth and on Doppler flow velocity waveforms. Early Hum Dev 24:23–36[CrossRef][Medline]
  9. Bruner JP, Forouzan I 1991 Smoking and buccally administered nicotine. Acute effect on uterine and umbilical artery Doppler flow velocity waveforms. J Reprod Med 36:435–440[Medline]
  10. Castro LC, Allen R, Ogunyemi D, Roll K, Platt LD 1993 Cigarette smoking during pregnancy: acute effects on uterine flow velocity waveforms. Obstet Gynecol 81:551–555[Abstract/Free Full Text]
  11. Larsen LG, Clausen HV, Jønsson L 2002 Stereologic examination of placentas from mothers who smoke during pregnancy. Am J Obstet Gynecol 186:531–537[CrossRef][Medline]
  12. Van der Velde WJ, Trefers PE 1985 Smoking in pregnancy: the influence on percentile birth weight, mean birth weight, placental weight, menstrual age, perinatal mortality and maternal diastolic blood pressure. Gynecol Obstet Invest 19:57–63[Medline]
  13. Pfarrer C, Macara L, Leiser R, Kingdom J 1999 Adaptive angiogenesis in placentas of heavy smokers. Lancet 354:303[CrossRef][Medline]
  14. Bureau MA, Shapcott D, Berthiamme Y, Monette J, Bloun D, Blanchard P, Begin R 1983 Maternal cigarette smoking and fetal oxygen transport: a study of P50, 2,3 diphosphoglycerate, total haemoglobin, hematocrit and type F haemoglobin in fetal blood. Pediatrics 72:22–26[Abstract/Free Full Text]
  15. De Chiara TM, Efstratiadis A, Robertson EJ 1990 A growth deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345:78–81[CrossRef][Medline]
  16. Gluckman PD, Johnson-Barrett JJ, Butler JH, Edgar BW, Gunn TR 1983 Studies of the insulin-like growth factor I and II by specific radioligands in umbilical cord blood. Clin Endocrinol (Oxf) 1983 19:405–413[Medline]
  17. Ashton IK, Eischenk I, McKenzie IZ 1985 Insulin-like growth factors (IGF) 1 and 2 in human foetal plasma and relationship to gestation age and foetal size during midpregnancy. Acta Endocrinol (Copenh) 110:558–563[Medline]
  18. Verhaeghe J, Van Bree R, Van Herck E, Laureys J, Bouillon R, Van Assche FA 1993 C-peptide, insulin-like growth factors I and II, and insulin-like growth factor binding protein-1 in umbilical cord serum: Correlations with birth weight. Am J Obstet Gynecol 169:89–97[Medline]
  19. Reece EA, Wizniter A, Le E, Homko CJ, Behrman H, Spencer EM 1994 The relation between human fetal growth and fetal blood levels of insulin-like growth factors I and II, their binding proteins, and receptors. Obstet Gynecol 84:88–95[Abstract/Free Full Text]
  20. Langford KS, Nicolaides KH, Jones J, Abbas A, McGregor AM, Miell JP 1995 Serum insulin-like growth factor-binding protein-3 (IGFBP-3) levels and IGFBP-3 protease activity in normal, abnormal and multiple human pregnancy. J Clin Endocrinol Metab 80:21–27[Abstract]
  21. Davey DA, MacGillivray I 1988 The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 158:892–898[Medline]
  22. Arduini D, Rizzo G 1990 Normal values of pulsatility index from fetal vessels: a cross-sectional study on 1556 healthy fetuses. J Perinat Med 18:165–172[Medline]
  23. Grannum PAT, Berkowitz RL, Hobbins JC 1979 The ultrasound changes in the maturing placenta and their relationship to fetal pulmonic maturity. Am J Obstet Gynecol 133:915–922[Medline]
  24. Freeman JV, Cole TJ, Chinn S, Jones PRM, White EM, Preece MA 1995 Cross-sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 73:17–24[Abstract]
  25. Armitage P, Berry G 1994 Statistical methods in medical research. 3rd ed. Oxford, UK: Blackwell Science; 292–311
  26. Haworth JC, Ellestad-Sayed JJ, King J, Dilling LA 1980 Fetal growth retardation in cigarette-smoking mothers is not due to decreased maternal food intake. Am J Obstet Gynecol 137:719–723[Medline]
  27. Souza SW, Black PM, Williams N, Jennison RF 1978 Effect of smoking during pregnancy upon the haematological values of cord blood. Br J Obstet Gynaecol 85:495–499[Medline]
  28. Demir R, Demir AY, Yinanc M 1994 Structural changes in placental barrier of smoking mother. A quantitative and ultrastructural study. Pathol Res Pract 190:656–667[Medline]
  29. Law CM, Barker DJP, Bull AR, Osmond C 1991 Maternal and fetal influences on blood pressure. Arch Dis Child 66:1291–1295[Abstract]
  30. D’Souza SW, Black P, Richards B 1981 Smoking in pregnancy: associations with skinfold thickness, maternal weight gain, and fetal size at birth. BMJ 282:1661–1663
  31. Harrison GG, Branson RS, Vaucher YE 1983 Association of maternal smoking with body composition of the newborn. Am J Clin Nutr 38:757–762[Abstract/Free Full Text]
  32. Wattanapenpaiboon N, Lukito W, Strauss BJ, Hsu-Hage BH, Wahlqvist ML, Stroud DB 1998 Agreement of skinfold measurement and bioelectrical impedance analysis (BIA) methods with dual energy X-ray absorptiometry (DEXA) in estimating total body fat in Anglo-Celtic Australians. Int J Obes Relat Metab Disord 22:854–860[CrossRef][Medline]
  33. Tanner JM 1989 Fetus into Man. 2nd ed. Ware, UK: Castlemead Publications; 36
  34. Cairns NJ, Wonnacott S 1988 [3H] nicotine binding sites in fetal human brain. Brain Res 475:1–7[CrossRef][Medline]
  35. Slotkin TA, Lappi SE, Seidler FJ 1991 Impact of fetal nicotine exposure on development of rat brain regions: critical sensitive periods or effect of withdrawal? Brain Res Bull 31:319–328
  36. Iwamoto HS, Murray MA, Chernausek SD 1992 Effects of acute hypoxaemia on insulin-like growth factors and their binding proteins in sheep. Am J Physiol 263:E1151–E1156



This article has been cited by other articles:


Home page
Clin. Chem.Home page
C. Chiesa, J. F. Osborn, C. Haass, F. Natale, M. Spinelli, E. Scapillati, A. Spinelli, and L. Pacifico
Ghrelin, Leptin, IGF-1, IGFBP-3, and Insulin Concentrations at Birth: Is There a Relationship with Fetal Growth and Neonatal Anthropometry?
Clin. Chem., March 1, 2008; 54(3): 550 - 558.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. C. Geerts, D. E. Grobbee, C. K. van der Ent, B. M. de Jong, M. M. van der Zalm, N. van Putte-Katier, J. L.L. Kimpen, and C. S.P.M. Uiterwaal
Tobacco Smoke Exposure of Pregnant Mothers and Blood Pressure in Their Newborns: Results from the Wheezing Illnesses Study Leidsche Rijn Birth Cohort
Hypertension, September 1, 2007; 50(3): 572 - 578.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
P. Saenger, P. Czernichow, I. Hughes, and E. O. Reiter
Small for Gestational Age: Short Stature and Beyond
Endocr. Rev., April 1, 2007; 28(2): 219 - 251.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/5/2556    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pringle, P. J.
Right arrow Articles by Hindmarsh, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pringle, P. J.
Right arrow Articles by Hindmarsh, P. C.
Related Collections
Right arrow Pediatric Endocrinology


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals